Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2021-12-27

Summary

This phase II trial studies how well ibrutinib and brentuximab vedotin work in treating patients with Hodgkin lymphoma that has returned (relapsed) or does not respond to treatment (refractory). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as brentuximab vedotin, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving ibrutinib together with brentuximab vedotin may be a better treatment for Hodgkin lymphoma.

• Phase: Phase 2

Details

• Lead Sponsor: City of Hope Medical Center
• Collaborators: National Cancer Institute (NCI); Pharmacyclics LLC.
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Brentuximab Vedotin; Immunoconjugates; Immunoglobulins